BIBF 1120/nintedanib: A new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer

Expert Opinion on Investigational Drugs

Volumn 22, Issue 8, 2013, Pages 1081-1088

  Rolfo, Christian ^a   Raez, Luis E ^b   Bronte, Giuseppe ^c   Santos, Edgardo S ^d   Papadimitriou, Kostantinos ^a   Buffoni, Lucio ^e   Van Meerbeeck, Jan P ^f   Russo, Antonio ^c  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b Memorial Health Care System   (United States)

^c UNIVERSITY OF PALERMO   (Italy)

^d Lynn Cancer Institute   (United States)

^e MOLINETTE HOSPITAL   (Italy)

^f GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Anti angiogenesis; BIBF 1120; Nintedanib; Non small cell lung cancer; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CD135 ANTIGEN; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; FIBROBLAST GROWTH FACTOR RECEPTOR; GEMCITABINE; NINTEDANIB; PACLITAXEL; PEMETREXED; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; TISSUE PLASMINOGEN ACTIVATOR; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ABDOMINAL PAIN; ADRENAL CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGIOGENESIS; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; COLORECTAL CARCINOMA; CONFUSION; CYTOTOXICITY; DIARRHEA; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOXICITY; ESOPHAGUS PAIN; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; INTRACELLULAR SIGNALING; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; METASTASIS; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; PANCREATIC NEUROENDOCRINE TUMOR; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN BINDING; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SKIN REDNESS; SOLID TUMOR; THERAPY EFFECT; THROMBOCYTOPENIA; THYROID CANCER; TREATMENT RESPONSE; TUMOR GROWTH; VOMITING;

ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; INDOLES; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 84880212274     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.812630     Document Type: Article

References (50)

1. Carmeliet P, Jain R. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57
2. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82(1):4-6
3. Hicklin D, Ellis L. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23(5):1011-27
4. Weidner N. Tumoural vascularity as a prognostic factor in cancer patients: The evidence continues to grow. J Pathol 1998;184:119-22
5. Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 2004;25:581-611
6. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005;69(Suppl 3):4-10
7. Bremnes R, Camps C, Sirera R. Angiogenesis in non-small cell lung cancer: The prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 2006;51(2):143-58
8. Jain R. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 2001;7:987-9
9. Giaccone G. The potential of antiangiogenic therapy in non-small cell lung cancer. Clin Cancer Res 2007;13:1961-70
10. Clement-Duchene C, Wakelee H. Antiangiogenic agents and vascular disrupting agents for the treatment of lung cancer: A review. J Thorac Oncol 2010;5:129-39
11. McKeage M, Baguley B. Disrupting established tumor blood vessels: An emerging therapeutic strategy for cancer. Cancer 2010;116:1859-71
12. Jain R, Booth M. What brings pericytes to tumor vessels? J Clin Invest 2003;112:1134-6
13. Cao Y, Cao R, Hedlund EM. R Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways. J Mol Med 2008;86:785-9
14. Erber R, Thurnher A, Katsen A, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004;18:338-40
15. Shih A, Holland E. Platelet-derived growth factor (PDGF) and glial tumorigenesis. Cancer Lett 2006;232:139-47
16. Beenken A, Mohammadi M. The FGF family: Biology, pathophysiology and therapy. Nat Rev Drug Discov 2009;8:235-53
17. Presta M, Dell'Era P, Mitola S, et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005;16:159-78
18. Rosen LS. Clinical experience with angiogenesis signaling inhibitors: Focus on vascular endothelial growth factor (VEGF) blockers. Cancer Contr 2002;9:36-44
19. Bergers G, Song S, Meyer-Morse N, et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111:1287-95
20. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309
21. Ferrara N, Hillan K, Gerber H, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400
22. Avastin- (bevacizumab) [package insert]. Genentech, Inc, South San Francisco, CA; 2009
23. Herbst R. Toxicities of antiangiogenic therapy in non-small-cell lung cancer. Clin Lung Cancer 2006;8:S23-30
24. Spigel D, Hainsworth J, Yardley D, et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol 2010;28:43-8
25. Scagliotti G, Novello S, Von P, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010;28:1835-42
26. Wilhelm S, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109
27. NEXAVAR (sorafenib) tablets, oral [package insert]. Bayer Healthcare Pharmaceuticals Inc, Wayne, NJ; 2009
28. Escudier B, Eisen T, Stadler W, et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27:3312-18
29. Llovet J, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
30. Scagliotti G, Novello S, von Pawel J, Reck M. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. JCO 2010;28(11):835-42
31. Paz-Ares LG, Biesma B, Heigener D, et al. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol 2012;30:25):3084-92
32. Heng D, Kollmannsberger C. Sunitinib. Recent Results Cancer Res 2010;184:71-82
33. SUTENT- (sunitinib malate) capsules, oral [package insert]. Pfizer Inc, New York, NY; 2010
34. Socinski M, Novello S, Brahmer J, et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008;26:650-6
35. Novello S, Scagliotti G, Rosell R, et al. Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer 2009;101:1543-8
36. United States Federal Drug Administration (FDA): FDA approves new treatment for rare form of thyroid cancer. Vandetanib is first drug approved for medullary thyroid cancer. 2013. Available from: Http://www.fda. gov/NewsEvents/Newsroom/PressAnnouncements/ucm250168.htm
37. Mitsudomi T. Advances in target therapy for lung cancer. Jpn J Clin Oncol 2010;40:101-6
38. AstraZeneca Oncology 2009. Vandetanib (Zactima-). Available from: Http://www. astrazeneca.com/Media/Press-releases/Article/20091028- AstraZenecawithdraws-regulatory-submissions-for-Zact [Accessed 29 April 2013]
39. Wells S, Robinson B, Gagel R, et al. [Abstract OC-021]. Presented at the 14th International Thyroid Conference; 11 -16 September 2010; Paris, France
40. Natale R, Thongprasert S, Greco F, et al. Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: A randomized, double-blind phase III trial (ZEST) [abstract 8009]. J Clin Oncol 2009;27:409s
41. De Boer R, Arrieta O, Gottfried M, et al. Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZEAL) [abstract 8010]. J Clin Oncol 2009;27:409s
42. Herbst RS, Sun Y, Eberhardt WE, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): A double-blind, randomised, phase 3 trial. Lancet Oncol 2010;11:619-26
43. Lee J, Hirsh V, Park K, et al. Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: A randomized . double-blind phase III trial (ZEPHYR). J Clin Oncol 2010;28:7525
44. Hilberg F, Roth G, Krssak M, et al. BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008;68:4774-82
45. Roth G, Heckel A, Colbatzky F, et al. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J Med Chem 2009;52:4466-80
46. Hilberg F, Brandstetter I. Efficacy of BIBF 1120, a potent triple angiokinase inhibitor, in models of human non-small cell lung cancer is augmented by chemotherapy: C7-03. J Thoracic Oncol 2007;2(8):S380
47. Mross K, Stefanic M, Gmehling D, et al. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res 2010;16:311-19
48. Okamoto I, Kaneda H, Satoh T, et al. Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors. Mol Cancer Ther 2010;9(10):2825-33
49. Ellis PM, Kaiser R, Zhao Y, et al. Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients. Clin Cancer Res 2010;16(10):2881-9
50. Doebele RC, Conkling P, Traynor AM, et al. A phase I, open-label doseescalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced nonsmall-cell lung cancer. Ann Oncol 2012;23(8):2094-102